SynthesisToxins2020
Human Biomonitoring of Mycotoxins in Blood, Plasma and Serum in Recent Years: A Review.
Synthesis in Toxins, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 105 citations in OpenAlex.
- Review
- Chronic exposure to aflatoxin B1, ochratoxin A, and citrinin in women and children and associated health risk characterization: blood biomonitoring evidence from rural Bangladesh.Environmental health : a global access science source · 2026Article
- Aflatoxin BJournal of fungi (Basel, Switzerland) · 2026Article
- Biomonitoring of Occupational Exposure to Mycotoxins Among Swine Farm Workers: An Italian Pilot Study.Toxics · 2026Article
- Review
- The Difficulties in Demonstrating That Aflatoxin Reduction Improves Stunting in Developing World Regions.Toxins · 2026Review
- Climate-stressed crop mycobiomes as pre-harvest sentinels of human mycotoxin exposure: an AI-enabled One Health framework linking dysbiosis, exposomics, and toxicopathology.Frontiers in systems biology · 2026Review
- Mycotoxins and plant diseases in a changing climate: from pathogen ecology to smart surveillance and mitigation strategies.Frontiers in fungal biology · 2026Review
- Aflatoxin B1 modulates mixture-induced neurotoxicity under multi-contaminant exposure: insights from combination modeling in SH-SY5Y cells.Frontiers in pharmacology · 2026Article
- Human biomonitoring of mycotoxins: key challenges and future directions.Mycotoxin research · 2025Review
- Impact of Aflatoxins on the Digestive, Immune, and Nervous Systems: The Role of Microbiota and Probiotics in Toxicity Protection.International journal of molecular sciences · 2025Review
- Aflatoxin Exposure in Immunocompromised Patients: Current State and Future Perspectives.Toxins · 2025Review
- Article
- Maize consumption and circulating aflatoxin levels in Mexican middle- and older-aged adults: a cross-sectional analysis.The American journal of clinical nutrition · 2025Article
- Multiple mycotoxin exposure assessment through human biomonitoring in an esophageal cancer case-control study in the Arsi-Bale districts of Oromia region of Ethiopia.International journal of hygiene and environmental health · 2025Article
- Ochratoxin A Status at Birth Is Associated with Reduced Birth Weight and Ponderal Index in Rural Burkina Faso.The Journal of nutrition · 2025Article
- Ochratoxin A in food commodities: A review of occurrence, toxicity, and management strategies.Heliyon · 2024Review
- The Potential of Multi-Screening Methods and Omics Technologies to Detect Both Regulated and Emerging Mycotoxins in Different Matrices.Foods (Basel, Switzerland) · 2024Review
- Monitoring Mycotoxin Exposure in Food-Producing Animals (Cattle, Pig, Poultry, and Sheep).Toxins · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
This manuscript reviews the state-of-the-art regarding human biological monitoring (HBM) of mycotoxins in plasma serum and blood samples. After a comprehensive and systematic literature review, with a focus on the last five years, several aspects were analyzed and summarized: a) the biomarkers analyzed and their encountered levels, b) the analytical methodologies developed and c) the relationship between biomarker levels and some illnesses. In the literature reviewed, aflatoxin B1-lysine (AFB1-lys) and ochratoxin A (OTA) in plasma and serum were the most widely studied mycotoxin biomarkers for HBM. Regarding analytical methodologies, a clear increase in the development of methods for the simultaneous determination of multiple mycotoxins has been observed. For this purpose, the use of liquid chromatography (LC) methodologies, especially when coupled with tandem mass spectrometry (MS/MS) or high resolution mass spectrometry (HRMS), has grown. A high percentage of the samples analyzed for OTA or aflatoxin B1 (mostly as AFB1-lys) in the reviewed papers were positive, demonstrating human exposure to mycotoxins. This review confirms the importance of mycotoxin human biomonitoring and highlights the important challenges that should be faced, such as the inclusion of other mycotoxins in HBM programs, the need to increase knowledge of mycotoxin metabolism and toxicokinetics, and the need for reference materials and new methodologies for treating samples. In addition, guidelines are required for analytical method validation, as well as equations to establish the relationship between human fluid levels and mycotoxin intake.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.